This report covers the 7MM (US, France, Germany, Italy, Spain, UK, Japan) and provides an Excel-based forecast model for the Female Contraceptives market through 2032.
The publisher estimates 2022 global contraceptives sales to total approximately $7.8 billion across the 7MM covered within this report. The US contributed 74.6% of these sales, generating an estimated $5.8 billion in 2022. Germany was the largest market of the 5EU, with an estimated $642.9 million in sales in 2022 out of the $1.9 billion total 5EU sales. Japan had the least sales of the 7MM, contributing 1.2% of total sales in 2022 and 1.0% in 2023.
Late-stage pipeline therapies are anticipated to drive slight but not significant growth in the contraceptives market.
Hormonal contraceptives with reduced adverse reactions, non-hormonal contraceptives, better compliance and adherence to contraceptives, access to a wide range of contraceptives and awareness of different contraceptive methods are the greatest unmet needs in the contraceptives space.
The publisher estimates 2022 global contraceptives sales to total approximately $7.8 billion across the 7MM covered within this report. The US contributed 74.6% of these sales, generating an estimated $5.8 billion in 2022. Germany was the largest market of the 5EU, with an estimated $642.9 million in sales in 2022 out of the $1.9 billion total 5EU sales. Japan had the least sales of the 7MM, contributing 1.2% of total sales in 2022 and 1.0% in 2023.
Key Highlights
Female contraceptives market will slightly grow during the forecast period, at a CAGR of 0.5%.Late-stage pipeline therapies are anticipated to drive slight but not significant growth in the contraceptives market.
Hormonal contraceptives with reduced adverse reactions, non-hormonal contraceptives, better compliance and adherence to contraceptives, access to a wide range of contraceptives and awareness of different contraceptive methods are the greatest unmet needs in the contraceptives space.
Scope
- Overview of Female Contraceptives
- Annualized Female Contraceptives therapeutics market revenue, cost of therapy per patient, and treatment usage patterns forecast from 2022 to 2032.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping, and implications of these factors for the Female Contraceptives therapeutics market.
- Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for Female Contraceptives. The most promising candidates in late-stage development are profiled.
- Analysis of the current and future market competition in the global Female Contraceptive therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
Reasons to Buy
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the 7MM Female Contraceptives therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the 7MM Female Contraceptives therapeutics market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
Table of Contents
- About the Publisher
1 Female Contraceptives: Executive Summary
2 Introduction
3 Disease Overview
4 Current Treatment Options
5 Unmet Needs and Opportunity Assessment
6 R&D Strategies
7 Pipeline Assessment
8 Pipeline Valuation Analysis
9 Current and Future Players
10 Market Outlook
11 Appendix
List of Tables
List of Figures
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Bayer
- Agile Therapeutics
- Pfizer
- Organon
- Evofem Biosciences
- Merk
- Allergen
- Population Council
- Mithra Pharmaceutics
- Exeltis
- ASKA Pharmaceuticals co. LTd
- FujiPharma
